Spire Biomedical, Inc., • One Patriots Park • Bedford, MA 01730-2396
TEL (781) 275-6000 •FAX 781 275 6010

**SECTION 5 - 510(k) SUMMARY**

JAN 2 9 2007

15.5Fr Decathlon Gold, Coated Catheters with funnel tips

**Date:** November 2, 2006

**Submitter:**
Spire Biomedical, Inc.
One Patriots Park
Bedford, MA 01730-2396
Phone: (781) 275-6000
Fax: (781) 275-7470

**Contact Person:**
Shekhar Nimkar
Director of Product Development and Manufacturing
Spire Biomedical, Inc.
Phone: (781) 275-6001 x203
Fax: (781) 275-6010
email: snimkar@spirecorp.com

**Device Names:**

| | |
|---|---|
| *Trade Name:* | 15.5Fr Decathlon Gold, Coated Catheters with funnel tips |
| *Common Name:* | Catheter, Intravascular, Long-Term |
| *Classification Name:* | Catheter, Hemodialysis, Implant (Long-Term) |
| *Classification:* | Class III |
| *Device Code:* | *78 MSD* |

Spire Biomedical, Inc., • One Patriots Park • Bedford, MA 01730-2396
TEL (781) 275-6000 •FAX 781 275 6010

## 510(k) Summary (Continued)

### Device Description:

Spire Biomedical, Inc.'s 15.5Fr Decathlon Gold, Coated catheters are processed with a proprietary Carmeda® BioActive Surface (CBAS®) coating technology that attaches a functionally active heparin to the surfaces of the device. The coating counteracts thrombus from forming on the catheter. Spire's 15.5Fr Decathlon Gold, Coated catheters are fully coated with CBAS® on the internal surface and on the external surface of the catheter body (from 2cm distal to the cuff to the ends of the distal tips; the cuff is not coated). The distal ends of this catheter have the arterial and venous tips rounded and "funneled" for easier over the wire insertion. It has one elliptical side hole placed on the distal ends of the arterial and venous lumens. A stylet will be preloaded in the arterial lumen for ease of guidewire placement.

The coating is essentially non-leaching. Additionally, the maximum amount of heparin on the surface is only 1mg. Therefore; the effects of the entire coating on a patient's coagulation status would be insignificant.

### Product Claims:

As demonstrated in two *in-vitro* study, the proprietary End-Point Bonded Heparin Coating attachment mechanism anchors heparin molecules to both internal and external surfaces of the catheter while maintaining heparin's bioactive properties for a minimum of 90 days.[1]

Coating bioactivity was assessed in 90-day durability tests performed on coated catheters in saline. Surface-bound heparin bioactivity (in $pmol/cm^2$) was assessed at each of seven regular intervals. Heparin bioactivity remained essentially constant throughout the test period, demonstrating that the coating's bioactive properties were maintained.

*In-vitro* studies have demonstrated that the coating reduces total thrombus accumulation by 51% compared to uncoated catheters. The coating was effective in mitigating both disturbed flow-mediated thrombosis (at the catheter tip) and fibrin sheath propagation (on the catheter shaft). [1]

The two-hour *in-vitro* thromboresistance study involved circulation of bovine blood through an outer loop, in which a coated or uncoated catheter was placed. Simultaneously, blood was circulated through the catheter at a constant flow rate. Three criteria were used to determine the effects of the coating in reducing thrombus formation: Pressure increase in the arterial lumen; visual evaluation of the catheters; and end point thrombus accumulation. Results show improved thromboresistance using each of these criteria for Decathlon Gold, coated catheters with funnel tips vs. uncoated catheters. End-point thrombus radiolabeled measurements showed an average of 51% reduction in thrombus accumulation for two hours for coated catheters.

---

[1] Data on file

Spire Biomedical, Inc., • One Patriots Park • Bedford, MA 01730-2396
TEL (781) 275-6000 •FAX 781 275 6010

## Technological Characteristics Comparison to Predicate Devices:

The 15.5Fr Decathlon Gold, coated catheter with funnel tips is identical to the Coated Decathlon catheter (K060155) in physical characteristics, namely, materials of construction, dimensions, and the coating. The only difference is the distal tips, which are funneled for easier over the wire insertions.

The Carmeda® BioActive Surface (CBAS®) coating has been approved for the following legally marketed devices to which substantial equivalence is claimed:

1. Spire Biomedical coated Decathlon (K060155)
2. Medtronic Maxima cardiopulmonary bypass circuit (K925626 and K933586)
3. Diametrics Paratrend intravascular blood gas sensor catheter (K970906)
4. Cordis Bx Velocity coronary stent (P900043/S024)

## Performance Data:

The data from the coated Decathlon (K060155) were not duplicated for the Decathlon Gold with funnel tips since the materials of construction, the dimensions, and the coating are identical to the coated Decathlon with the exception of the distal arterial and venous tips. The following tests were conducted on the predicate device but are not repeated here:

- Stability (leaching) for 90 days
- Durability testing (Accelerated aging for one year)
- Mechanical properties (Tensile strength)

The following additional tests were conducted on the Decathlon Gold catheters with funnel tips to demonstrate coating performance claims:

- Two hour In-vitro blood loop testing.
- Catheter flows (bench testing)

DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850

Mr. Shekhar Nimkar
Director of Product Development and Manufacturing
Spire Biomedical, Inc.
One Patriots Park
BEDFORD MA 01730-2396

JAN 2 9 2007

Re: K063431
Trade/Device Name: 15.5Fr Decathlon Gold, Coated Twin Lumen Chronic Hemodialysis Catheter with Separated Funnel Tips
Regulation Number: 21 CFR §876.5540
Regulation Name: Blood access device and accessories
Regulatory Class: III
Product Code: MSD
Dated: November 2, 2006
Received: November 13, 2006

Dear Mr. Nimkar:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. However, you are responsible to determine that the medical devices you use as components in the kit have either been determined as substantially equivalent under the premarket notification process (Section 510(k) of the act), or were legally on the market prior to May 28, 1976, the enactment date of the Medical Device Amendments. *Please note:* If you purchase your device components in bulk (i.e., unfinished) and further process (e.g., sterilize) you must submit a new 510(k) before including these components in your kit. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, and labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration (21 CFR Part 807); listing (21 CFR Part 807), labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market. If you desire specific advice for your device on the labeling regulation, please contact the Office of Compliance at (240) 276-0115. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll free number (800) 638-2041 or (301) 443-6597, or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

for Nancy C. Brogdon
Director, Division of Reproductive,
Abdominal, and Radiological Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure

K063431

Spire Biomedical, Inc., • One Patriots Park • Bedford, MA 01730-2396
TEL (781) 275-6000 •FAX 781 275 6010

## SECTION 4 - INDICATIONS FOR INTENDED USE

510(k) Number (if known) K063431

**Device Name:** 15.5Fr Decathlon Gold, Coated Twin Lumen Chronic Hemodialysis Catheter with Separated Funnel Tips

**Indications for Use:** Spire Biomedical Inc's Decathlon Gold, Coated Twin Lumen Chronic Hemodialysis Catheter with separated funnel tips is designed for chronic hemodialysis and apheresis. It is a radiopaque polyurethane with a heparin coating, designed for percutaneous insertion or insertion via cutdown. The ability of the Carmeda® End point Bonded Heparin Coating to reduce clotting is supported by in-vitro testing. Catheters longer than 40cm are intended for femoral vein insertion.

Prescription Use √ AND/OR Over-the-Counter Use _____
(Part 21 CFR 801 Subpart D) (Part 21 CFR 801 Subpart C)

David B. Lepore

(Division Sign-Off)
Division of Reproductive, Abdominal,
and Radiological Devices
510(k) Number K063431

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

---

Concurrence of CDRH, Office of Device Evaluation (ODE)